ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

Roughly 50% of hypertrophic cardiomyopathies (HCM) are obstructive, and of this percentage, most of symptoms can be attributed to this condition. Historically, it has been treated with non-specific drugs such as betablockers or calcium blockers. 

ACC 2022 - Estudio VALOR-HCM

There is an alternative treatment, septal reduction therapy (SRT), done either by surgery myectomy and alcohol septal ablation, both normally done in specialized centers. 

In recent years, we have been using a drug called Mavacamten that specifically inhibits actin myosin cross bridges, reducing HCM myocardial hyper contractibility.

The aim of this study was to assess the safety and efficacy of adding Mavacamten to maximally tolerated medical therapy among patients with HCM who were considering TRS (surgical or percutaneous) as an alternative, after 16 weeks of treatment. 

It included patients with conserved ejection fraction, septal width ≥15mm to ≥13 with a family history of HCM, severe symptoms despite maximally tolerated medical therapy, with dynamic LVOT gradient at rest or with provocation (Valsalva maneuver or exercise) ≥50 mm Hg.

Read also: ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries.

Patients receiving Mavacamten significantly reduced TSR requirement, 17.0 vs 76.8% (p < 0.0001), with improved functional class, lower resting and stress gradient vs. placebo. With no important adverse events. 

Conclusions

Like the EXPLORER-HCM (improved compared functional capacity with placebo) the use of Mavacamten improved symptoms and significantly reduced the need for TRS after 16 weeks, with no adverse events.  

It looks like a great alternative for serious patients despite medical treatment; we still need to find out how it behaves at long term and to assess harder outcomes such as mortality and hospitalization. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the editorial board, SOLACI.org

Original Title: VALOR HCM: Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy – VALOR-HCM

Reference: Presented by Dr. Milind Y. Desai in the Annual Sessions of the American College of Cardiology (ACC 2022), Washington, Abril 2, 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....